Publications
2025
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.
Munro, A. P. S., Drysdale, S. B., Cathie, K., Flamein, F., Knuf, M., Collins, A. M., . . . HARMONIE Study Group. (2025). 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.. The Lancet. Child & adolescent health, 9(6), 404-412. doi:10.1016/s2352-4642(25)00102-6
2023
Surveillance towards preventing paediatric incidence of respiratory syncytial virus attributable respiratory tract infection in primary and secondary/tertiary healthcare settings in Merseyside, Cheshire and Bristol, UK
Fyles, F., Hill, H., Duncan, G., Carter, E., Solorzano, C., Davies, K., . . . Collins, A. M. (2023). Surveillance towards preventing paediatric incidence of respiratory syncytial virus attributable respiratory tract infection in primary and secondary/tertiary healthcare settings in Merseyside, Cheshire and Bristol, UK. BMJ OPEN RESPIRATORY RESEARCH, 10(1). doi:10.1136/bmjresp-2022-001457